Paul Peter Tak | BiotechTV

top of page

ASCO 2025: Candel Therapeutics CEO Paul Peter Tak describes phase 3 prostate cancer data from the company's off-the-shelf, adeno delivered, cancer immunotherapy

He explains the design of the therapy, and covers the data presented at ASCO. Plus, filing and manufacturing plans, and highlighting this...

Company News

Jun 2

Candel Therapeutics CEO Paul Peter Tak and IDEA Pharma CEO Mike Rea on why they believe a different mindset and good communication are keys to succeeding with new innovations in biotech

They discuss the difference between how biotech companies operate from large pharmas, including how history shows some new biotech...

Company News

Apr 1

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page

ASCO 2025: Candel Therapeutics CEO Paul Peter Tak describes phase 3 prostate cancer data from the company's off-the-shelf, adeno delivered, cancer immunotherapy

Candel Therapeutics CEO Paul Peter Tak and IDEA Pharma CEO Mike Rea on why they believe a different mindset and good communication are keys to succeeding with new innovations in biotech

Follow BiotechTV

Sponsors

Sponsor Spotlight